Transmedics Group (TMDX)
NASDAQ:TMDX
Want to see TMDX full AI Analyst Report?
Total Valuation
TransMedics Group has a market cap or net worth of $2.35B. The enterprise value is $2.74B.
Market Cap$2.35B
Enterprise Value$2.74B
Share Statistics
TransMedics Group has 34,560,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,560,910
Owned by Insiders3.48%
Owned by Institutions22.41%
Financial Efficiency
TransMedics Group’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 10.94%.
Return on Equity (ROE)0.40
Return on Assets (ROA)0.18
Return on Invested Capital (ROIC)10.94%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee831.72K
Profits Per Employee261.39K
Employee Count728
Asset Turnover0.57
Inventory Turnover4.96
Valuation Ratios
The current PE Ratio of TransMedics Group is 116.8. TransMedics Group’s PEG ratio is 0.05.
PE Ratio116.8
PS Ratio6.83
PB Ratio8.74
Price to Fair Value8.74
Price to FCF30.96
Price to Operating Cash Flow10.76
PEG Ratio0.05
Income Statement
In the last 12 months, TransMedics Group had revenue of 605.49M and earned 190.29M in profits. Earnings per share was 5.60.
Revenue605.49M
Gross Profit362.81M
Operating Income108.58M
Pretax Income107.52M
Net Income190.29M
EBITDA148.49M
Earnings Per Share (EPS)5.60
Cash Flow
In the last 12 months, operating cash flow was 220.23M and capital expenditures -68.87M, giving a free cash flow of 151.36M billion.
Operating Cash Flow220.23M
Free Cash Flow151.36M
Free Cash Flow per Share4.38
Dividends & Yields
TransMedics Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.08
52-Week Price Change-44.52%
50-Day Moving Average98.73
200-Day Moving Average119.73
Relative Strength Index (RSI)31.64
Average Volume (3m)1.52M
Important Dates
TransMedics Group upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 5, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
TransMedics Group as a current ratio of 7.14, with Debt / Equity ratio of 165.74%
Current Ratio7.14
Quick Ratio6.59
Debt to Market Cap0.11
Net Debt to EBITDA-0.13
Interest Coverage Ratio7.88
Taxes
In the past 12 months, TransMedics Group has paid -82.77M in taxes.
Income Tax-82.77M
Effective Tax Rate-0.77
Enterprise Valuation
TransMedics Group EV to EBITDA ratio is 27.72, with an EV/FCF ratio of 30.82.
EV to Sales6.80
EV to EBITDA27.72
EV to Free Cash Flow30.82
EV to Operating Cash Flow21.35
Balance Sheet
TransMedics Group has $461.74M in cash and marketable securities with $818.75M in debt, giving a net cash position of -$357.01M billion.
Cash & Marketable Securities$461.74M
Total Debt$818.75M
Net Cash-$357.01M
Net Cash Per Share-$10.33
Tangible Book Value Per Share$13.52
Margins
Gross margin is 59.09%, with operating margin of 17.93%, and net profit margin of 31.43%.
Gross Margin59.09%
Operating Margin17.93%
Pretax Margin17.76%
Net Profit Margin31.43%
EBITDA Margin24.52%
EBIT Margin20.03%
Analyst Forecast
The average price target for TransMedics Group is $130.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$130.80
Price Target Upside12.89% Upside
Analyst ConsensusModerate Buy
Analyst Count11
Revenue Growth Forecast30.24%
EPS Growth Forecast244.83%